LY3537982

Phase 2Small molecule

Eli Lilly

LY3537982 is one of 93 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsActive, not recruiting

FunctionRecruiting

KRAS G12CRecruiting

Advanced Solid TumorsPhase 1

Active, not recruiting

FunctionPhase 1

Recruiting

KRAS G12CPhase 2

Recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

19 2

Fludara

Sanofi

Phase 2

16 3

Avastin

Roche

Phase 2

15 4

Paraplatin

AAvyxa

Phase 2

32 5

Abraxane

Bristol-Myers Squibb

Phase 2

11 6

Imfinzi

AstraZeneca

Phase 2

10 7

Lenvima

Eisai

Phase 2

5 8

Libtayo

Regeneron

Phase 2

4 9

Erbitux

Braftovi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

KRAS G12C

NCT04956640

Phase 1Active, not recruiting

Advanced Solid Tumors

NCT06235983

Q1 2031

Phase 3Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06119581

Clinical

Trials by Indication[1]

ART2 trials

A Study of [14C]-LY3537982 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05901311·16 enrolled

A Study of the Effect of Food on LY3537982 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05824858·48 enrolled

CAR1 trial

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05860933·30 enrolled

Function1 trial

A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07137689·32 enrolled

Interaction1 trial

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06111521·35 enrolled

KRAS G12C1 trial

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04956640·540 enrolled

2 more indications

Advanced Solid Tumors1 trial

A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06235983·12 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06119581·1,264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for LY3537982. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY3537982 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY3537982. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY3537982

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2031

Trials by Indication[1]

ART2 trials

CAR1 trial

Function1 trial

Interaction1 trial

KRAS G12C1 trial

Advanced Solid Tumors1 trial

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News